Home › Premarket Biotech Digest: Exelixis' Milestone, Valeant's Investor Call, Sophiris Soars
 

Keywords :   


Premarket Biotech Digest: Exelixis' Milestone, Valeant's Investor Call, Sophiris Soars

2015-11-12 05:49:58| Biotech - Topix.net

Click this link to find out how much you can save.) Exelixis achieved a major milestone on Tuesday as the company's Cotellic was approved by the FDA as a treatment for patients with BRAF V600E or V600K mutation-positive unresectable or metastatic melanoma in combination with Zelboraf. Cotellic has already been approved in Switzerland earlier this year.

Tags: call investor digest biotech

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
20.05Eastern North Pacific Tropical Weather Outlook
20.05Atlantic Tropical Weather Outlook
20.05We Recycle Solar Expands Partnership with Renewables.org
20.05Washington State Authorizes Drone for Methane Emissions
20.05The Heart, Science & Business of Sustainability: A Fireside Chat with Tara Hemmer
20.05Commissioners Celebrate the Opening of New Waste Transfer Station in Redmond, Ore.
20.05Newhaven Food Waste Facility Plans Paused Following Residents Concerns
20.05Business Report May 2024Highlights from WasteExpo 2024
More »